Skip to main content
Journal cover image

Carotid Restenosis Following Endarterectomy in Patients Managed With Single Antiplatelet Therapy Versus Dual Antiplatelet Therapy.

Publication ,  Journal Article
Glotzer, OS; Rojas, E; Bouchard, DR; Hill, SS; Harad, FT; Zhang, Z; Bowser, KE
Published in: Vasc Endovascular Surg
April 2021

BACKGROUND: Antiplatelet therapy is a cornerstone in the management of carotid artery disease following carotid endarterectomy (CEA). There is a paucity of data regarding the effect of dual antiplatelet therapy (DAPT) on restenosis rates. METHODS: A retrospective review of patients who underwent CEA from January 1, 2007 to December 31, 2013 was performed at a single center. Study groups consisted of subjects who received DAPT and those who received single antiplatelet therapy (SAPT) following CEA. Restenosis was evaluated by carotid duplex. Severity and timing of restenosis, postoperative complications, and reinterventions were compared between study groups. RESULTS: Between January 1, 2007 and December 31, 2013, 1453 patients underwent CEA. The SAPT group consisted of 245 patients and the DAPT group consisted of 1208 patients. No difference in restenosis was identified between groups at less than 6 weeks (6.5% vs. 11.7% 50-79% stenosis, 0% vs. 2.2% 80-99% stenosis, 2.2% vs. 0.6% occlusion, p = 0.368), and 6 weeks to 2 years (20.6% vs. 17.9% 50-79% stenosis, 1.1% vs. 1.0% 80-99% stenosis, 1.6% vs. 0.4% occlusion, p = 0.242). A higher rate of restenosis in SAPT was found greater than 2 years from surgery (68.4% vs. 82.4% <50% stenosis, 29.9% vs. 16.1% 50-79% stenosis, 0% vs. 0.6% 80-99% stenosis, 1.7% vs. 0.9% occlusion p = 0.004). This finding persisted on multivariable analysis with 31.6% of the SAPT group showing >50% stenosis vs. 17.6% of the DAPT group (adjusted OR 0.48, 95% CI 0.30-0.76, p = 0.002). In a propensity matched-population, 32.7% of the SAPT group demonstrated restenosis vs. 13.7% of the DAPT group (adjusted OR 0.35, 95% CI 0.16-0.77, p = 0.009). There was no difference in the need for reintervention between study groups (DAPT 3.8% vs SAPT 3.3%, p = 0.684). CONCLUSION: Following CEA, patients on DAPT exhibited lower rates of late restenosis. Despite this finding, a clinical difference in reintervention was not found during this study period.

Duke Scholars

Published In

Vasc Endovascular Surg

DOI

EISSN

1938-9116

Publication Date

April 2021

Volume

55

Issue

3

Start / End Page

209 / 215

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Retreatment
  • Recurrence
  • Platelet Aggregation Inhibitors
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Glotzer, O. S., Rojas, E., Bouchard, D. R., Hill, S. S., Harad, F. T., Zhang, Z., & Bowser, K. E. (2021). Carotid Restenosis Following Endarterectomy in Patients Managed With Single Antiplatelet Therapy Versus Dual Antiplatelet Therapy. Vasc Endovascular Surg, 55(3), 209–215. https://doi.org/10.1177/1538574420975908
Glotzer, Owen S., Elianne Rojas, David Roberge Bouchard, Susanna S. Hill, F Todd Harad, Zugui Zhang, and Kathryn E. Bowser. “Carotid Restenosis Following Endarterectomy in Patients Managed With Single Antiplatelet Therapy Versus Dual Antiplatelet Therapy.Vasc Endovascular Surg 55, no. 3 (April 2021): 209–15. https://doi.org/10.1177/1538574420975908.
Glotzer OS, Rojas E, Bouchard DR, Hill SS, Harad FT, Zhang Z, et al. Carotid Restenosis Following Endarterectomy in Patients Managed With Single Antiplatelet Therapy Versus Dual Antiplatelet Therapy. Vasc Endovascular Surg. 2021 Apr;55(3):209–15.
Glotzer, Owen S., et al. “Carotid Restenosis Following Endarterectomy in Patients Managed With Single Antiplatelet Therapy Versus Dual Antiplatelet Therapy.Vasc Endovascular Surg, vol. 55, no. 3, Apr. 2021, pp. 209–15. Pubmed, doi:10.1177/1538574420975908.
Glotzer OS, Rojas E, Bouchard DR, Hill SS, Harad FT, Zhang Z, Bowser KE. Carotid Restenosis Following Endarterectomy in Patients Managed With Single Antiplatelet Therapy Versus Dual Antiplatelet Therapy. Vasc Endovascular Surg. 2021 Apr;55(3):209–215.
Journal cover image

Published In

Vasc Endovascular Surg

DOI

EISSN

1938-9116

Publication Date

April 2021

Volume

55

Issue

3

Start / End Page

209 / 215

Location

United States

Related Subject Headings

  • Treatment Outcome
  • Time Factors
  • Risk Factors
  • Risk Assessment
  • Retrospective Studies
  • Retreatment
  • Recurrence
  • Platelet Aggregation Inhibitors
  • Middle Aged
  • Male